1,011 reports of this reaction
6.0% of all TIMOLOL MALEATE reports
#1 most reported adverse reaction
TREATMENT FAILURE is the #1 most commonly reported adverse reaction for TIMOLOL MALEATE, manufactured by Bausch & Lomb Incorporated. There are 1,011 FDA adverse event reports linking TIMOLOL MALEATE to TREATMENT FAILURE. This represents approximately 6.0% of all 16,822 adverse event reports for this drug.
Patients taking TIMOLOL MALEATE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is moderately reported among TIMOLOL MALEATE users, representing a notable but not dominant share of adverse events.
In addition to treatment failure, the following adverse reactions have been reported for TIMOLOL MALEATE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 1,011 FDA reports for TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 6.0% of all adverse event reports for TIMOLOL MALEATE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.